Discovery and Preclinical Pharmacology of a Selective ATP-Competitive Akt Inhibitor (GDC-0068) for the Treatment of Human Tumors

Citations Over TimeTop 10% of 2012 papers

Abstract

The discovery and optimization of a series of 6,7-dihydro-5H-cyclopenta[d]pyrimidine compounds that are ATP-competitive, selective inhibitors of protein kinase B/Akt is reported. The initial design and optimization was guided by the use of X-ray structures of inhibitors in complex with Akt1 and the closely related protein kinase A. The resulting compounds demonstrate potent inhibition of all three Akt isoforms in biochemical assays and poor inhibition of other members of the cAMP-dependent protein kinase/protein kinase G/protein kinase C extended family and block the phosphorylation of multiple downstream targets of Akt in human cancer cell lines. Biological studies with one such compound, 28 (GDC-0068), demonstrate good oral exposure resulting in dose-dependent pharmacodynamic effects on downstream biomarkers and a robust antitumor response in xenograft models in which the phosphatidylinositol 3-kinase-Akt-mammalian target of rapamycin pathway is activated. 28 is currently being evaluated in human clinical trials for the treatment of cancer.

Related Papers

• → Mechanisms and consequences of activation of protein kinase B/Akt(1998)1,306 cited
• → The Akt kinases: Isoform specificity in metabolism and cancer(2009)468 cited
• → Insulin-modulated Akt subcellular localization determines Akt isoform-specific signaling(2009)187 cited
• → Combined targeting of AKT and mTOR using MK‐2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma(2013)86 cited
• → Towards an understanding of protein kinase B (PKB/Akt) function in mouse development(2004)